Latest Comments

Big pharma fails to challenge UK price controls as court backs NICE

Big pharma fails to challenge UK price controls as court backs NICE

Repealing the ACA: the Graham-Cassidy Bill’s impact on expanded Medicaid coverage

Repealing the ACA: the Graham-Cassidy Bill’s impact on expanded Medicaid coverage

Safety concerns cloud Ocaliva’s future prospects in NASH

Safety concerns cloud Ocaliva’s future prospects in NASH

Over two thirds of women unaware of sodium valproate safety risks

Over two thirds of women unaware of sodium valproate safety risks

GSK Announces Planned Regulatory Filing of Nucala – Will the IL-5 Inhibitor Mark the First Approved Biologic for COPD?

GSK Announces Planned Regulatory Filing of Nucala – Will the IL-5 Inhibitor Mark the First Approved Biologic for COPD?

Green pharma: The growing demand for environmentally friendly drugs

Green pharma: The growing demand for environmentally friendly drugs

Is the Neulasta molecule too complex for biosimilar developers to crack?

Is the Neulasta molecule too complex for biosimilar developers to crack?

ESMO 2017: An uncertain future for Merck’s Keytruda

ESMO 2017: An uncertain future for Merck’s Keytruda

An update on PARP inhibitors: ovarian cancer and beyond

An update on PARP inhibitors: ovarian cancer and beyond

Ten-year old NICE restrictions on Velcade limit patient access to next-gen therapies

Ten-year old NICE restrictions on Velcade limit patient access to next-gen therapies

Array BioPharma’s BRAF/MEK combination set for approval review in Europe

Array BioPharma’s BRAF/MEK combination set for approval review in Europe

FDA rejection of Acorda’s Inbrija is another challenge after Ampyra patent setback

FDA rejection of Acorda’s Inbrija is another challenge after Ampyra patent setback

ESC Congress Barcelona 2017 Highlights – What is the Role of Monotherapies in the Treatment of PAH Patients?

ESC Congress Barcelona 2017 Highlights – What is the Role of Monotherapies in the Treatment of PAH Patients?

High Multiple Sclerosis Costs Are Attracting Attention From US Lawmakers

High Multiple Sclerosis Costs Are Attracting Attention From US Lawmakers

Despite Humira patent expiry, Abbvie is poised to remain a market leader in Crohn’s disease

Despite Humira patent expiry, Abbvie is poised to remain a market leader in Crohn’s disease

PARP inhibitors are set to become the new standard of care in BRCA1/2-mutated pancreatic adenocarcinoma

PARP inhibitors are set to become the new standard of care in BRCA1/2-mutated pancreatic adenocarcinoma

The future of vaccines – could they really grow on trees?

The future of vaccines – could they really grow on trees?

Anti-nerve growth factor antibodies expected to drive osteoarthritis market growth

Anti-nerve growth factor antibodies expected to drive osteoarthritis market growth

BMS shifts towards precision medicine

BMS shifts towards precision medicine

pSivida and Alimera enter new phase of collaboration on the longest-acting ocular steroid implant

pSivida and Alimera enter new phase of collaboration on the longest-acting ocular steroid implant

Dynavax’s Heplisav-B passes key regulatory hurdle with FDA Advisory Committee endorsement

Dynavax’s Heplisav-B passes key regulatory hurdle with FDA Advisory Committee endorsement